News Briefs: AstraZeneca Will Withdraw Lumoxiti From the U.S. Market

AstraZeneca will permanently withdraw Lumoxiti (moxetumomab pasudotox-tdfk) from the U.S. market, the company revealed recently. In a letter to health care providers, the company said it will direct its distributors to halt distribution of the agent in August 2023 and will request that those distributors return any Lumoxiti packs. The FDA approved the medication on Sept. 13, 2018, for the treatment of relapsed or refractory hairy cell leukemia in people who had received at least two prior systemic therapies including a purine nucleoside analog. The manufacturer said that the drug’s withdrawal is not related to its safety or efficacy and that the medicine has had “very low clinical uptake” since its approval, “due to the availability of other treatment options and possibly due to the specialized complexity of administration, toxicity prophylaxis and safety monitoring needs for patients.” The company advised providers not to start treatment of the drug. For patients already taking it, providers have “adequate time to complete six cycles of treatment.”

0

0

0 Comments

0

0

• Radar on Specialty Pharmacy